ATG16L2 and myeloid sarcoma: Expression of ATG16L2, an isoform of ATG16L that inhibits ATG12-ATG5-ATG16L1 complex formation, was reduced in the serum of MS patients and this reduction was suggested to be mechanistically linked to defective T cell homeostasis in these patients (19).